Patent Coverage Leads Indian Drug Makers Into Ties With Foreign Firms
This article was originally published in PharmAsia News
Executive Summary
India's three year old ban on generic copies of drugs still under patent coverage has led the pharma industry to turn to inlicensing and strategic marketing deals with foreign companies. A pharma researcher said the deals offer higher margins, between 25 percent and 35 percent, without competition from other generics. Ranbaxy Laboratories has the largest number of ties with other drug makers, allowing it to launch 12 new products in the recent three month period. The ties also lower the amount of investments needed in the business and fewer risks. (Click here for more
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.